Pulmonary Artery Denervation Significantly Increases 6-Min Walk Distance for Patients With Combined Pre- and Post-Capillary Pulmonary Hypertension Associated With Left Heart Failure

• Published in: JACC. Cardiovascular interventions Vol. 12; no. 3; pp. 274 - 284
• Main Authors: Zhang, Hang, Zhang, Juan, Chen, Mengxuan, Xie, Du-Jiang, Kan, Jing, Yu, Wande, Li, Xiao-Bo, Xu, Tian, Gu, Yue, Dong, Jianzeng, Gu, Hong, Han, Yaling, Chen, Shao-Liang
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 11.02.2019
• Subjects: 6-min walk distance; heart failure; pulmonary artery denervation; pulmonary hypertension; mPAP; pulmonary hypertension; LVEF; CpcPH; HR; HFpEF; RHC; HFrEF; IpcPH; PVR; pulmonary artery denervation; PADN; WU; heart failure; 6-min walk distance; CI; PCWP; CO; PA; PAC; PE; PAH; PH; DPG; 6MWD; HF; PAP
• ISSN: 1936-8798; 1876-7605
• DOI: 10.1016/j.jcin.2018.09.021

The authors sought to assess the benefits of pulmonary artery denervation (PADN) among combined pre- and post-capillary pulmonary hypertension (CpcPH) patients in a prospective, randomized, sham-controlled trial. PADN has been shown to improve hemodynamics of pulmonary arterial hypertension in a series of patients. Additionally, benefits of targeted medical therapy for patients with CpcPH secondary to left-sided heart failure are unknown. Ninety-eight CpcPH patients, defined as mean pulmonary arterial pressure ≥25 mm Hg, pulmonary capillary wedge pressure >15 mm Hg, and pulmonary vascular resistance (PVR) >3.0 Wood units (WU), were randomly assigned to PADN or sildenafil plus sham PADN. Standard medical therapy for heart failure was administered to all patients in both groups. The primary endpoint was the increase in the 6-min walk distance at the 6-month follow-up. The secondary endpoint was change in PVR. Clinical worsening was assessed in a post hoc analysis. The main safety endpoint was occurrence of pulmonary embolism. At 6 months, the mean increases in the 6-min walk distance were 83 m in the PADN group and 15 m in the sildenafil group (least square mean difference 66 m, 95% confidence interval: 38.2 to 98.8 m; p < 0.001). PADN treatment was associated with a significantly lower PVR than in the sildenafil group (4.2 ± 1.5 WU vs. 6.1 ± 2.9 WU; p = 0.001). Clinical worsening was less frequent in the PADN group compared with the sildenafil group (16.7% vs. 40%; p = 0.014). At the end of the study, there were 7 all-cause deaths and 2 cases of pulmonary embolism. PADN is associated with significant improvements in hemodynamic and clinical outcomes in patients with CpcPH. Further studies are warranted to define its precise role in the treatment of this patient population. (Pulmonary Arterial Denervation in Patients With Pulmonary Hypertension Associated With the Left Heart Failure [PADN-5]; NCT02220335) [Display omitted]